3 directorsName after signing inVisible after signing in and 2 others
Documentsfilings and deeds
30-09-202561 days late
2024micro format
Gross margin from -€264,505 to €436,169Profit of €241,143, after a lossEquity from €140,911 to €382,053Debts from €429,957 to €611,730Investments €85,000Cash from €105,959 to €36,709
Higher net result than 95% of companies in office administrative support. The sector median is €13,996, over 9,496 companies.
2025 accounts not filed, 113 days past the deadline
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 39,330 companies had the same profile as PharmaBXL has now. Each dot stands for 99 companies, two years later.
95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
Micro
2 to 5 years old
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.4%
0.5%
3
0.6%
0.6%
4
0.7%
0.8%
5
0.9%
1.0%
6
1.4%
1.6%
7
1.7%
1.8%
8
1.9%
2.0%
9
3.1%
3.3%
10
5.9%
6.4%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,330 companies, not a prediction for PharmaBXL. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Registered office moved from Berchem-Sainte-Agathe to Brussels
The registered office moved from Koekelberglaan 1, 1082 SINT-AGATHA-BERCHEM to Zavelput 17, 1000 BRUSSEL · Board meeting of 01-06-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0795508480
New managing directorName hiddenVisible after signing in appointed, Hidden nameVisible after signing in resigned · Name after signing inVisible after signing in and Name hiddenVisible after signing in act as permanent representatives · Board meeting of 13-02-2026 · Gazette deed
1 director appointed, 2 resignations
110,208 new shares · 5,402,453 new shares · Hidden nameVisible after signing in and Name after signing inVisible after signing in resign · General meeting of 30-12-2025 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as PharmaBXL: other business support services (NACE 82990). They are comparable in size and age: total assets between €763,000 and €1.1m, founded between 2022 and 2023.
The 2024 annual accounts show equity of €382,053 and a net result of €241,143, with €242,565 of non-recurring income. Its solvency ranks better than 40% of 9,497 sector peers (NACE 82) in financial year 2024.
The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.
According to the KBO register, the main activity is other business support services (NACE 82990).
What is the legal form of PharmaBXL?
PharmaBXL is a private limited company (BV).
When was PharmaBXL founded?
PharmaBXL was founded on 29-12-2022.
Is PharmaBXL still active?
Yes, PharmaBXL is an active enterprise in the KBO register.
How many employees does PharmaBXL have?
PharmaBXL had an average of 0.1 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
Which joint committee does PharmaBXL fall under?
In its 2024 annual accounts, PharmaBXL states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of PharmaBXL?
The turnover in financial year 2024 is about €650,000. This figure is estimated from the gross margin of €436,169 and 33 comparable companies (NACE 82990). It probably lies between €540,000 and €920,000.
Is PharmaBXL profitable?
In financial year 2024, PharmaBXL made a profit of €241,143.
Where can I find the annual accounts of PharmaBXL?
PharmaBXL filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
When are the next annual accounts of PharmaBXL due?
PharmaBXL had to file the annual accounts for financial year 2025 by 31-07-2026. On 21-11-2026 they are not filed yet, 113 days past the deadline.Timeline